Thursday, December 26, 2024
12/26/2024
Synaptic disruption is a prelude to and often a primary cause of neurological disease, but we have few strategies to correct dysmorphic synapses, even if they occur early in the degenerative process. Growth control pathways, i.e. those that promote protein and lipid synthesis while reducing catabolism, regulate synaptic form that in turn ensures efficient function and plasticity. The 7-pass endosomal membrane protein TMEM184B regulates synaptic structure and function across species; accordingly, its loss causes exuberant synaptic sprouting, swollen nerve terminals, and altered excitability. In humans, disruption of conserved amino acids in TMEM184B is linked to nervous system disruptions including microcephaly, intellectual disability, corpus callosum hypoplasia, and epilepsy. While TMEM184B genetic disruptions are rare, the disorders produced by TMEM184B disruption are common, suggesting an intersection with key neurological pathways. Our long-term goal is to define the mechanisms underlying TMEM184B variant-associated nervous system disorders in order to provide mechanistic guidance for their treatment. Our overall objectives in this proposal are to determine how TMEM184B directs key signaling pathways supporting neuronal structure and function and to illuminate how patient variants of TMEM184B alter synaptic transmission and resultant behavior. TMEM184B has sequence similarity to bile acid and sterol transporters, but this proposed molecular function remains untested. Preliminary data and published studies suggest an intersection between TMEM184B and mTOR, but how TMEM184B influences mTOR pathway activity is completely unknown. We hypothesize that TMEM184B is an endosomal transporter whose function impacts mTORC1 signaling to promote synaptic structure and function. In Aim1, we will evaluate the specific contributions of TMEM184B to the mTORC1 pathway using primary cortical neuron cultures from wild type and TMEM184B mutant mice. We will evaluate the function of upstream activators and downstream effectors of mTORC1 using functional readouts as well as lipidomic and phospho-proteomic tools. In Aim 2, we will model human disease-linked TMEM184B variants in Drosophila by introducing patient mutations into conserved amino acids. With these flies we will evaluate synaptic form, function (electrophysiological recording), and behavior. In Aim 3, we will establish the molecular function of the TMEM184B protein using a combination of in silico, thermodynamic, and proteomic assays to reveal candidate transport substrates and other metabolites most affected by TMEM184B disruption. Overall, our multifaced approach will illuminate the mechanism through which TMEM184B acts to ensure synaptic morphology and function while enabling a better classification of TMEM184B-associated disorders with others of similar etiology, facilitating improved diagnosis and treatment.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).